Press Releases Ovid Therapeutics Inc.

Equities

OVID

US6904691010

Market Closed - Nasdaq Other stock markets 04:30:01 2024-05-03 pm EDT			5-day change	1st Jan Change
3.06 ^USD	-0.33%		-1.29%	-4.97%

Apr. 30	B. Riley Securities Initiates Ovid Therapeutics With Buy Rating, $9 Price Target	MT
Apr. 29	HC Wainwright Starts Ovid Therapeutics With Buy Rating, $9 Price Target	MT

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Ovid Therapeutics to Present at the 23rd Annual Needham Virtual Healthcare Conference	Apr. 04	GL
Marinus Pharmaceuticals Comments on Patent Challenge by Ovid Therapeutics Inc. and Provides Update on Marinus Post Grant Review	Mar. 28	AQ
Ovid Therapeutics : Corporate Presentation	Mar. 08	PU
Ovid Therapeutics Reports Business Updates, Fourth Quarter and Full Year 2023 Financial Results	Mar. 08	GL
Ovid Therapeutics Reports Business Updates, Fourth Quarter and Full Year 2023 Financial Results	Mar. 08	AQ
Ovid Therapeutics to Present at the TD Cowen 44th Annual Health Care Conference	Feb. 28	GL
Ovid Therapeutics to Present at the TD Cowen 44th Annual Health Care Conference	Feb. 28	AQ
Ovid Therapeutics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference	Feb. 06	GL
Ovid Therapeutics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference	Feb. 06	AQ
Ovid Therapeutics to Present Five Abstracts Supporting its Epilepsy Programs at the 77th American Epilepsy Society Annual Meeting	Dec. 04	AQ
Ovid Therapeutics to Present Five Abstracts Supporting its Epilepsy Programs at the 77th American Epilepsy Society Annual Meeting (2023)	Dec. 01	GL
Ovid Therapeutics to Present Five Abstracts Supporting its Epilepsy Programs at the 77th American Epilepsy Society Annual Meeting (2023)	Dec. 01	AQ
Ovid Therapeutics : Corporate Presentation	Nov. 03	PU
Ovid Therapeutics Reports Third Quarter 2023 Financial Results and Corporate Updates	Nov. 03	GL
Ovid Therapeutics and Ligand Pharmaceuticals Enter into a $30 Million Agreement for a 13% Interest in Soticlestat Royalties and Milestones Extending Ovid's Cash Runway into 2026	23-10-19	AQ
Ovid Therapeutics and Ligand Pharmaceuticals Enter into a $30 Million Agreement for a 13% Interest in Soticlestat Royalties and Milestones Extending Ovid’s Cash Runway into 2026	23-10-18	GL
Ovid Therapeutics and Ligand Pharmaceuticals Enter into a $30 Million Agreement for a 13% Interest in Soticlestat Royalties and Milestones Extending Ovid’s Cash Runway into 2026	23-10-18	AQ
Ovid Therapeutics to Present at the Jefferies Biotech CNS/Neuro Summit	23-10-10	GL
Ovid Therapeutics to Present at the Jefferies Biotech CNS/Neuro Summit	23-10-10	AQ
Ovid Therapeutics to Host Investor Event, R&D Day on Monday, October 2, 2023	23-09-27	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Ovid Therapeutics Inc.

Equities

OVID

US6904691010

Press Releases

Filters